{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:17:53Z","timestamp":1784726273150,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01417-y","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:10:15Z","timestamp":1745464215000},"page":"1543-1553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-3324","authenticated-orcid":false,"given":"Kent A.","family":"Hanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7494","authenticated-orcid":false,"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-8069","authenticated-orcid":false,"given":"Andrew","family":"Messenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6053-6703","authenticated-orcid":false,"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6158-8076","authenticated-orcid":false,"given":"Lynne","family":"Napatalung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-7107","authenticated-orcid":false,"given":"Keith L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzi","family":"Esterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"3","key":"1417_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1417_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257\u201365.","journal-title":"Br J Dermatol"},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1417_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"MA Richard","year":"2018","unstructured":"Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u00ab\u202fOBJECTIFS PEAU\u202f\u00bb study. J Eur Acad Dermatol Venereol. 2018;32(11):1967\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1417_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"E Darwin","year":"2018","unstructured":"Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51\u201360.","journal-title":"Int J Trichology"},{"issue":"2","key":"1417_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177\u201388 (quiz 89\u201390).","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1417_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Austral J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"1417_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1417_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13555-023-00941-z","volume":"13","author":"N Mesinkovska","year":"2023","unstructured":"Mesinkovska N, Craiglow B, Ball SG, et al. The invisible impact of a visible disease: psychosocial impact of alopecia areata. Dermatol Ther (Heidelb). 2023;13(7):1503\u201315.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1417_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76.","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"1417_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000466704","volume":"3","author":"T Christensen","year":"2017","unstructured":"Christensen T, Yang JS, Castelo-Soccio L. Bullying and quality of life in pediatric alopecia areata. Skin Append Disord. 2017;3(3):115\u20138.","journal-title":"Skin Appendage Disord"},{"issue":"18","key":"1417_CR12","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase\u00a03 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"key":"1417_CR13","doi-asserted-by":"crossref","unstructured":"Senna M, King B, Mesinkovska A, Mostaghimi A, Hamilton C, Cassella J. Efficacy of the oral JAK1\/JAK2 inhibitor deuruxolitinib in adult patients with moderate to severe alopecia areata: pooled results from the multinational double-blind, placebo-controlled THRIVE-AA1 and THRIVE-AA2 phase\u00a03 trials. Presented at: AAD Annual Meeting; March 8\u201312, 2024; San Diego, CA. Abstract 51840. 2024.","DOI":"10.1016\/j.jaad.2024.07.161"},{"issue":"10387","key":"1417_CR14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase\u00a02b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"3","key":"1417_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1417_CR16","doi-asserted-by":"crossref","unstructured":"Vyas J, Johns JR, Abdelrazik Y, et al. The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: a\u00a0systematic review. J Eur Acad Dermatol Venereol. 2025;39(3):631\u201379.","DOI":"10.1111\/jdv.20321"},{"issue":"3","key":"1417_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Wikonk\u00e1l N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561\u201371.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1417_CR18","doi-asserted-by":"publisher","first-page":"s395","DOI":"10.25251\/skin.8.supp.395","volume":"8","author":"KL Davis","year":"2024","unstructured":"Davis KL, Messenger A, Va\u00f1\u00f3 Galv\u00e1n S, et al. Real-world assessment of disease characteristics and clinical outcomes in alopecia areata in a global noninterventional observational cohort (ADAAGIO). SKIN J Cutan Med. 2024;8(2):s395\u2013s395.","journal-title":"SKIN J Cutan Med"},{"issue":"4","key":"1417_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1417_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"L Liu","year":"2018","unstructured":"Liu L, King B, Craiglow B. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1417_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000497166","volume":"5","author":"RDC V\u00e9lez-Mu\u00f1iz","year":"2019","unstructured":"V\u00e9lez-Mu\u00f1iz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-S\u00e1nchez MA. Psychological profile and quality of life of patients with alopecia areata. Skin Append Disord. 2019;5(5):293\u20138.","journal-title":"Skin Appendage Disord"},{"issue":"6","key":"1417_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/1346-8138.16364","volume":"49","author":"T Ito","year":"2022","unstructured":"Ito T, Kamei K, Yuasa A, et al. Health-related quality of life in patients with alopecia areata: results of a Japanese survey with norm-based comparisons. J Dermatol. 2022;49(6):584\u201393.","journal-title":"J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01417-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T16:48:33Z","timestamp":1747759713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01417-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc. Ernest H. Law, Helen Tran, and Lynne Napatalung report employment with and stock ownership in Pfizer Inc. Kent A. Hanson served as a paid consultant to Pfizer during the period in which the work for this manuscript was conducted; the author is no longer affiliated with the company. Keith L. Davis and Lizzi Esterberg report employment with RTI Health Solutions, which received contract research funding from Pfizer Inc. for the conduct of this study. Andrew Messenger and Sergio Va\u00f1\u00f3-Galv\u00e1n report consultancy fees from Pfizer Inc. in relation to the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was subjected to ethics review and approval (or exemption, as applicable) based on local, country-specific requirements. In the UK, based on the National Health Service\u2019s Health Research Authority (HRA) online decision tool, the study was classified as a service evaluation or clinical\/non-financial audit; thus, the study was exempt from research ethics committee review (HRA decision tool certificate of exemption available upon request). In France, based on the retrospective, non-interventional study design in which only fully anonymized data were collected and retained, the study required only attestation of compliance with MR-004 (research methodology 004) to the Commission Nationale Informatique and Libert\u00e9s. In Germany, the study underwent independent ethics committee (IEC) review (with subsequent approval) with the Ethikkommission der Bayerischen Landes\u00e4rztekammer, in addition to notification of study conduct to the Ethikkommission der Bayerischen Landes\u00e4rztekammer. In Spain, IEC review (and subsequent approval) was obtained from Hospital Universitario La Paz, with competent authority notification to Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}